+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Rare Inflammatory Disease Treatment Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • July 2024
  • Region: Global
  • The Business Research Company
  • ID: 5983845
The rare inflammatory disease treatment market size has grown strongly in recent years. It will grow from $13.04 billion in 2023 to $13.82 billion in 2024 at a compound annual growth rate (CAGR) of 6%. The growth observed during the historic period can be attributed to several factors, including advances in immunology research, the emergence of targeted therapies, increased prevalence and awareness of rare inflammatory diseases, expanded utilization of biological agents, and the establishment of orphan drug regulations.

The rare inflammatory disease treatment market size is expected to see strong growth in the next few years. It will grow to $17.56 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to several factors, including accelerated drug development pipelines, increased investment in precision medicine, expanded availability of advanced diagnostics, rising prevalence and diagnosis rates of rare inflammatory diseases, and heightened efforts in patient advocacy and awareness. Key trends expected during this period include the adoption of personalized treatment approaches, integration of digital health solutions, a focus on patient-centered care, expansion of gene therapy options, and increased collaboration and data-sharing initiatives within the medical community.

The rise in autoimmune diseases is anticipated to drive the expansion of the rare inflammatory disease treatment market in the foreseeable future. Autoimmune diseases involve the immune system mistakenly attacking healthy cells and tissues, leading to inflammation and tissue damage. Factors contributing to the increase in autoimmune diseases include genetic predisposition, environmental triggers, lifestyle changes, and advancements in diagnostic techniques, resulting in improved detection and recognition of these conditions. Rare inflammatory disease treatments are commonly used to mitigate inflammation and prevent the immune system from targeting healthy tissues in patients with autoimmune disorders. For example, according to the International Osteoporosis Foundation's February 2021 report, over 300 million people worldwide suffer from rare diseases, affecting approximately 3.5% to 5.9% of the global population. Additionally, Health Match reported in November 2022 that there are approximately 150 rare kidney ailments globally, with high prevalence rates ranging from 60 to 80 incidences per 100,000 individuals in America and Europe. Hence, the increasing prevalence of autoimmune diseases is fueling the growth of the rare inflammatory disease treatment market.

Leading companies in the rare inflammatory disease treatment sector are concentrating on developing advanced precision medicines, such as monoclonal antibodies, to target specific aspects of the immune system and gain a competitive advantage. Monoclonal antibodies play a pivotal role in rare inflammatory disease treatments by focusing on particular pathways to alleviate symptoms and enhance patient outcomes. For instance, in January 2022, Boehringer Ingelheim, a pharmaceutical company based in Germany, obtained approval from the U.S. Food and Drug Administration (FDA) for SPEVIGO. This monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first approved medication for treating Generalized Pustular Psoriasis (GPP) in adults and adolescents aged 12 years and older, weighing at least 88 pounds (40 kg). SPEVIGO represents a targeted treatment approach aimed at suppressing interleukin-36 receptor (IL-36R) activity, a crucial component of an immune system signaling pathway implicated in GPP flares.

In March 2022, Pfizer Inc., a pharmaceutical company based in the United States, acquired Arena Pharmaceuticals for $6.7 billion. This strategic acquisition by Pfizer aimed to bolster its presence in the immuno-inflammatory diseases market and provide enhanced services to patients. Arena Pharmaceuticals, a U.S.-based clinical-stage company, specializes in developing innovative potential treatments for severe and rare inflammatory diseases.

Major companies operating in the rare inflammatory disease treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences, Inc., Amgen Inc., Regeneron Pharmaceuticals, Inc., Biogen Inc., UCB S.A., Jazz Pharmaceuticals plc, Horizon Therapeutics plc, Kyowa Kirin Co., Ltd., BioMarin Pharmaceutical Inc., Mallinckrodt Pharmaceuticals, Sarepta Therapeutics, Inc., Cytokinetics, Incorporated, Orchard Therapeutics plc.

North America was the largest region in the rare inflammatory disease treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare inflammatory disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare inflammatory disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Rare inflammatory disease treatment encompasses a range of therapeutic interventions and strategies aimed at managing symptoms, suppressing the inflammatory response, and potentially altering the disease's course in individuals affected by these uncommon inflammatory conditions. This includes pharmacological therapies, lifestyle adjustments, supportive care measures, and participation in clinical trials or experimental treatments.

The primary drug class for rare inflammatory disease treatment consists of biologics and organic compounds. Biologics are medications derived from living organisms or their components, such as proteins, antibodies, or nucleic acids, which target specific molecules involved in the disease process. They are administered via various routes, including injectables, oral medications, among others, and are indicated for conditions such as ulcerative colitis, juvenile rheumatoid arthritis, and psoriatic arthritis. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online pharmacies.

The rare inflammatory disease treatment market research report is one of a series of new reports that provides rare inflammatory disease treatment market statistics, including the rare inflammatory disease treatment industry global market size, regional shares, competitors with rare inflammatory disease treatment market share, detailed rare inflammatory disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the rare inflammatory disease treatment industry. This rare inflammatory disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rare inflammatory disease treatment market consists of revenues earned by entities by providing services such as clinical evaluation, parallel sequencing, targeted sequencing, laboratory testing, and specialist consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare inflammatory disease treatment market also includes sales of vision evaluation instruments, blood pressure cuffs, cardiac monitors, and advanced imaging equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Rare Inflammatory Disease Treatment Market Characteristics3. Rare Inflammatory Disease Treatment Market Trends and Strategies
4. Rare Inflammatory Disease Treatment Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Rare Inflammatory Disease Treatment Market Size and Growth
5.1. Global Rare Inflammatory Disease Treatment Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Rare Inflammatory Disease Treatment Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Rare Inflammatory Disease Treatment Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Rare Inflammatory Disease Treatment Market Segmentation
6.1. Global Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Biologics
  • Organic Compounds
6.2. Global Rare Inflammatory Disease Treatment Market, Segmentation by Mode of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Injectables
  • Oral
  • Other Administration Modes
6.3. Global Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ulcerative Colitis
  • Juvenile Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Other Indications
6.4. Global Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
7. Rare Inflammatory Disease Treatment Market Regional and Country Analysis
7.1. Global Rare Inflammatory Disease Treatment Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Rare Inflammatory Disease Treatment Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Rare Inflammatory Disease Treatment Market
8.1. Asia-Pacific Rare Inflammatory Disease Treatment Market Overview
(Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies)
8.2. Asia-Pacific Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Rare Inflammatory Disease Treatment Market
9.1. China Rare Inflammatory Disease Treatment Market Overview
9.2. China Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Rare Inflammatory Disease Treatment Market
10.1. India Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Rare Inflammatory Disease Treatment Market
11.1. Japan Rare Inflammatory Disease Treatment Market Overview
11.2. Japan Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Rare Inflammatory Disease Treatment Market
12.1. Australia Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Rare Inflammatory Disease Treatment Market
13.1. Indonesia Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Rare Inflammatory Disease Treatment Market
14.1. South Korea Rare Inflammatory Disease Treatment Market Overview
14.2. South Korea Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Rare Inflammatory Disease Treatment Market
15.1. Western Europe Rare Inflammatory Disease Treatment Market Overview
15.2. Western Europe Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Rare Inflammatory Disease Treatment Market
16.1. UK Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Rare Inflammatory Disease Treatment Market
17.1. Germany Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Rare Inflammatory Disease Treatment Market
18.1. France Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Rare Inflammatory Disease Treatment Market
19.1. Italy Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Rare Inflammatory Disease Treatment Market
20.1. Spain Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Rare Inflammatory Disease Treatment Market
21.1. Eastern Europe Rare Inflammatory Disease Treatment Market Overview
21.2. Eastern Europe Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Rare Inflammatory Disease Treatment Market
22.1. Russia Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Rare Inflammatory Disease Treatment Market
23.1. North America Rare Inflammatory Disease Treatment Market Overview
23.2. North America Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Rare Inflammatory Disease Treatment Market
24.1. USA Rare Inflammatory Disease Treatment Market Overview
24.2. USA Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Rare Inflammatory Disease Treatment Market
25.1. Canada Rare Inflammatory Disease Treatment Market Overview
25.2. Canada Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Rare Inflammatory Disease Treatment Market
26.1. South America Rare Inflammatory Disease Treatment Market Overview
26.2. South America Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Rare Inflammatory Disease Treatment Market
27.1. Brazil Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Rare Inflammatory Disease Treatment Market
28.1. Middle East Rare Inflammatory Disease Treatment Market Overview
28.2. Middle East Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Rare Inflammatory Disease Treatment Market
29.1. Africa Rare Inflammatory Disease Treatment Market Overview
29.2. Africa Rare Inflammatory Disease Treatment Market, Segmentation by Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Rare Inflammatory Disease Treatment Market, Segmentation by Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Rare Inflammatory Disease Treatment Market, Segmentation by Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Rare Inflammatory Disease Treatment Market Competitive Landscape and Company Profiles
30.1. Rare Inflammatory Disease Treatment Market Competitive Landscape
30.2. Rare Inflammatory Disease Treatment Market Company Profiles
30.2.1. Pfizer Inc.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Johnson & Johnson
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Roche Holding AG
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Merck & Co., Inc.
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. AbbVie Inc.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Rare Inflammatory Disease Treatment Market Other Major and Innovative Companies
31.1. Bayer AG
31.2. Sanofi S.a.
31.3. Bristol Myers Squibb
31.4. AstraZeneca Plc
31.5. Novartis AG
31.6. GlaxoSmithKline plc
31.7. Eli Lilly and Company
31.8. Gilead Sciences, Inc.
31.9. Amgen Inc.
31.10. Regeneron Pharmaceuticals, Inc.
31.11. Biogen Inc.
31.12. UCB S.a.
31.13. Jazz Pharmaceuticals plc
31.14. Horizon Therapeutics plc
31.15. Kyowa Kirin Co., Ltd.
32. Global Rare Inflammatory Disease Treatment Market Competitive Benchmarking33. Global Rare Inflammatory Disease Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Rare Inflammatory Disease Treatment Market
35. Rare Inflammatory Disease Treatment Market Future Outlook and Potential Analysis
35.1 Rare Inflammatory Disease Treatment Market in 2028 - Countries Offering Most New Opportunities
35.2 Rare Inflammatory Disease Treatment Market in 2028 - Segments Offering Most New Opportunities
35.3 Rare Inflammatory Disease Treatment Market in 2028 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Rare Inflammatory Disease Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare inflammatory disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for rare inflammatory disease treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rare inflammatory disease treatment market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Drug Class: Biologics; Organic Compounds
2) By Mode Of Administration: Injectables; Oral; Other Administration Modes
3) By Indication: Ulcerative Colitis; Juvenile Rheumatoid Arthritis; Psoriatic Arthritis; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co., Inc.; AbbVie Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Bayer AG
  • Sanofi S.A.
  • Bristol Myers Squibb
  • AstraZeneca Plc
  • Novartis AG
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Biogen Inc.
  • UCB S.A.
  • Jazz Pharmaceuticals plc
  • Horizon Therapeutics plc
  • Kyowa Kirin Co., Ltd.
  • BioMarin Pharmaceutical Inc.
  • Mallinckrodt Pharmaceuticals
  • Sarepta Therapeutics, Inc.
  • Cytokinetics, Incorporated
  • Orchard Therapeutics plc

Methodology

Loading
LOADING...

Table Information